StockData
Celularity Inc logo

Celularity Inc (CELU) stock

CELUNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Oct 20, 2026Score 7/30
$0.48−0.09 (-15.41%)

Close on Nov 18, 2026Market cap $15.68MP/E –Yield –

Celularity gross profit

Gross profit is revenue minus the direct cost of the goods and services sold.

Celularity's gross profit for the twelve months ending Jun 30, 2026 was $3.59M, down 85.4% year over year. For fiscal 2025 it was $6.48M, down 83.5% from the year before. The highest annual figure on record is $39.23M in fiscal 2024.

Annual gross profit

PeriodPeriod endValueChange
FY2025Dec 31, 2025$6.48M-83.5%
FY2024Dec 31, 2024$39.23M+480.8%
FY2023Dec 31, 2023$6.76M–
FY2022Dec 31, 2022-$1.69M-114.5%
FY2021Dec 31, 2021$11.68M+25.0%
FY2020Dec 31, 2020$9.35M–

Quarterly gross profit

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026$3.09M+524.5%
Q1 FY2026Mar 31, 2026$2.39M-69.6%
Q4 FY2025Dec 31, 2025-$3.27M-130.3%
Q3 FY2025Sep 30, 2025$1.38M-74.5%
Q2 FY2025Jun 30, 2025$494.00K-95.1%
Q1 FY2025Mar 31, 2025$7.87M-39.6%
Q4 FY2024Dec 31, 2024$10.79M+331.0%
Q3 FY2024Sep 30, 2024$5.41M+2841.8%
Q2 FY2024Jun 30, 2024$9.99M+367.6%
Q1 FY2024Mar 31, 2024$13.04M+575.0%
Q4 FY2023Dec 31, 2023$2.50M–
Q3 FY2023Sep 30, 2023$184.00K–
Q2 FY2023Jun 30, 2023$2.14M+257.8%
Q1 FY2023Mar 31, 2023$1.93M+1.2%
Q4 FY2022Dec 31, 2022-$1.12M-670.4%
Q3 FY2022Sep 30, 2022-$3.08M-137.0%
Q2 FY2022Jun 30, 2022$597.00K-66.0%
Q1 FY2022Mar 31, 2022$1.91M+34.6%
Q4 FY2021Dec 31, 2021$196.00K-90.5%
Q3 FY2021Sep 30, 2021$8.31M+257.9%
Q2 FY2021Jun 30, 2021$1.76M–
Q1 FY2021Mar 31, 2021$1.42M–
Q4 FY2020Dec 31, 2020$2.07M–
Q3 FY2020Sep 30, 2020$2.32M–

More Celularity figures

See a number that looks wrong?